Abstract
BackgroundTo evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. What is more, to compare SFCT and SFCT change between central RVO (CRVO) and branch RVO (BRVO).MethodsIn the retrospective study, we had collected 36-six treatment-naïve patients with unilateral ME secondary to RVO (including 19 CRVO and 17 BRVO). All patients had received IVR injection after newly diagnosed. The SFCT was measured at the onset and after 2 weeks of IVR injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. In further, independent t test was used to compare SFCT and SFCT change between CRVO eyes and BRVO eyes.ResultsThe mean SFCT at the onset was 326.03 ± 30.86 μm in CRVO eyes, which was significantly thicker than that in contralateral fellow eyes (p < 0.01, paired t test), and reduced to 294.15 ± 30.83 μm rapidly after 2 weeks of IVR injection (p < 0.01, paired t test). Similarly, the SFCT in BRVO eyes was significantly thicker than that in contralateral eyes at the onset, and decreased significantly after IVR injection. However, our findings showed that there was no statistically significant difference in SFCT and SFCT reduction after IVR injection between CRVO eyes and BRVO eyes.ConclusionsThe SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.
Highlights
To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection
Both central Retinal vein occlusion (RVO) (CRVO) and branch RVO (BRVO) can be further classified into non-ischemic subtype and ischemic subtype based on the amount of retinal capillary perfusion [5]
Inclusion criteria were as the follows: (1) the age ranged from 50 to 70 years; (2) recent-onset and treatment-naïve when presented to the hospital; (3) was ischemic subtype and had received at least one intravitreal ranibizumab injection after newly diagnosed; (4) had follow-up of at least 2 weeks; (5) had comprehensive ophthalmic examinations before and after treatment
Summary
To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. Retinal vein occlusion (RVO) is a retinal vascular disorder characterized by obstruction of the retinal venous system, often associated with hypertension and coagulation abnormalities [1, 2]. It is a common cause of visual handicap in the elderly throughout the world [3], and could be subdivided into central RVO (CRVO), branch RVO (BRVO) and hemi RVO (HRVO) according to the location of blockage [4]. Several studies had investigated subfoveal choroidal thickness (SFCT) in CRVO eyes and BRVO eyes, the results were contradictory. Most of the studies reported that the SFCT was decreased significantly after anti-VEGF
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
